[1] [1] QURASHI M, VITHAYATHIL M, KHAN S A. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2): 107064.

[2] [2] VITHAYATHIL M, KHAN S A. Current epidemiology of cholangiocarcinoma in western countries[J]. J Hepatol, 2022, 77(6): 1690-1698.

[3] [3] CANTALLOPS VIL P, RAVICHANDRA A, AGIRRE LIZASO A, et al. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma[J]. Hepatology, 2024, 79(4): 941-958.

[4] [4] CHEN L L, FAN Y G, ZHAO L X, et al. The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators[J]. Bioorg Chem, 2023, 131: 106301.

[5] [5] PRADO P , HFNER S, COMOGLIO Y, et al. KCNE1 is an auxiliary subunit of two distinct ion channel superfamilies[J]. Cell, 2021, 184(2): 534-544. e11.

[6] [6] SUN A W, WU M H, VIJAYALINGAM M, et al. The role of zinc in modulating acid-sensing ion channel function[J]. Biomolecules, 2023, 13(2): 229.

[7] [7] THOMPSON M W. Regulation of zinc-dependent enzymes by metal carrier proteins[J]. Biometals, 2022, 35(2): 187-213.

[8] [8] FUJISHIRO H, KAMBE T. Manganese transport in mammals by zinc transporter family proteins, ZNT and ZIP[J]. J Pharmacol Sci, 2022, 148(1): 125-133.

[9] [9] CHEN P H, WU J L, XU Y T, et al. Zinc transporter ZIP7 is a novel determinant of ferroptosis[J]. Cell Death Dis, 2021, 12(2): 198.

[10] [10] ZHU X Y, YU C X, WU W S, et al. Zinc transporter ZIP12 maintains zinc homeostasis and protects spermatogonia from oxidative stress during spermatogenesis[J]. Reprod Biol Endocrinol, 2022, 20(1): 17.

[11] [11] GUO H J, SU R Y, LU X F, et al. ZIP4 inhibits Ephrin-B1 ubiquitination, activating Wnt5A/JNK/ZEB1 to promote liver cancer metastasis[J]. Genes Dis, 2024, 11(6): 101312.

[12] [12] TANG Y P, GUO S, YU N H, et al. ZIP4: a promising early diagnostic and therapeutic targets for pancreatic cancer[J]. Am J Cancer Res, 2024, 14(9): 4652-4664.

[13] [13] TIAN T, LI J W, SHI D, et al. SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription[J]. Cell Death Dis, 2022, 13(9): 763.

[14] [14] FAN T, ZHU M C, MUHAMMAD S, et al. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma[J]. Respir Res, 2023, 24(1): 122.

[15] [15] MARSOLIER J, PROMPSY P, DURAND A, et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer[J]. Nat Genet, 2022, 54(4): 459-468.

[16] [16] TSAKANELI A, CARREGARI V C, MORINI M, et al. MYC regulates metabolism through vesicular transfer of glycolytic kinases[J]. Open Biol, 2021, 11(12): 210276.

[17] [17] LIU Z H, ZHANG X Y, XU M, et al. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription[J]. PLoS Biol, 2024, 22(3): e3002240.

[18] [18] UPTON K, MODI A, PATEL K, et al. Epigenomic profiling of neuroblastoma cell lines[J]. Sci Data, 2020, 7(1): 116.

[19] [19] LIU M Y, ZHANG Y Q, YANG J X, et al. Zinc-dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer[J]. Gastroenterology, 2021, 160(5): 1771-1783. e1.

[20] [20] JIANG Y Y, ZHAN H X, ZHANG Y Q, et al. ZIP4 promotes non-small cell lung cancer metastasis by activating snail-N-cadherin signaling axis[J]. Cancer Lett, 2021, 521: 71-81.

[21] [21] CHABANON R M, POSTEL-VINAY S. A novel synthetic lethal approach to target MYC-driven cancers[J]. Cancer Res, 2022, 82(6): 969-971.

[22] [22] KARADKHELKAR N M, LIN M L, EUBANKS L M, et al. Demystifying the druggability of the MYC family of oncogenes[J]. J Am Chem Soc, 2023, 145(6): 3259-3269.

[23] [23] TAO L, MOHAMMAD M A, MILAZZO G, et al. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma[J]. Nat Commun, 2022, 13(1): 3728.

[24] [24] LU Y X, YANG Q, SU Y B, et al. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma[J]. Cell Death Dis, 2021, 12(6): 511.

[25] [25] PAPADOPOULOS D, HA S A, FLEISCHHAUER D, et al. The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex[J]. Mol Cell, 2024, 84(11): 2070-2086.

[26] [26] ALBORZINIA H, FLREZ A F, KRETH S, et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis[J]. Nat Cancer, 2022, 3(4): 471-485.

[27] [27] VOLEGOVA M P, BROWN L E, BANERJEE U, et al. The MYCN 5' UTR as a therapeutic target in neuroblastoma[J]. Cell Rep, 2024, 43(5): 114134.

[28] [28] QIN X Y, SHIRAKAMI Y, HONDA M, et al. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence[J]. Int J Cancer, 2024, 155(3): 582-594.

[29] [29] ZARDO G. The role of H3K4 trimethylation in CpG islands hypermethylation in cancer[J]. Biomolecules, 2021, 11(2): 143.

[30] [30] GOLD S, SHILATIFARD A. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges[J]. J Clin Invest, 2024, 134(20): e183391.

[31] [31] HSU C L, LO Y C, KAO C F. H3K4 methylation in aging and metabolism[J]. Epigenomes, 2021, 5(2): 14.

[32] [32] LARSON J K, HUNTER-SCHLICHTING D N, CROWGEY E L, et al. KMT2A-D pathogenicity, prevalence, and variation according to a population database[J]. Cancer Med, 2023, 12(6): 7234-7245.